esmirtazapine
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sleep Initiation and Maintenance Disorders
Conditions
Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias, Sleep Disorders, Sleep Disorders, Intrinsic
Trial Timeline
Oct 7, 2008 → Mar 10, 2010
NCT ID
NCT00750919About esmirtazapine
esmirtazapine is a phase 3 stage product being developed by Merck for Sleep Initiation and Maintenance Disorders. The current trial status is terminated. This product is registered under clinical trial identifier NCT00750919. Target conditions include Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias.
What happened to similar drugs?
20 of 20 similar drugs in Sleep Initiation and Maintenance Disorders were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00750919 | Phase 3 | Terminated |
| NCT00561574 | Phase 3 | Completed |
Competing Products
20 competing products in Sleep Initiation and Maintenance Disorders